Trial to evaluate TNKase/Metalyse use prior to angioplasty.

2003 DEC 8 - (NewsRx.com & NewsRx.net) -- Boehringer Ingelheim and Genentech, Inc., announced that they plan to test the single-bolus thrombolytic TNKase/Metalyse (Tenecteplase) in combination with percutaneous coronary intervention (PCI, also known as primary angioplasty) as a potential treatment regimen for acute myocardial infarction (AMI).

The 4000-patient trial, ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction) has two arms: half the patients enrolled will receive a drug regimen consisting of a full-dose, single bolus of TNKase/Metalyse plus unfractionated heparin followed by immediate PCI. The other …